MetaCap

CNS Pharmaceuticals (CNSP) vs Tempest Therapeutics (TPST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tempest Therapeutics is the larger company by market cap ($5.7 million vs $5.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNSP-34.44%TPST-63.74%
+3%-32%-67%
Oct 7, 20261 yearNov 20, 2026
CNSP-33.46%TPST-62.24%
+3%-31%-65%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNSP versus TPST key metrics
MetricCNSPTPST
Share price$3.56$0.287
Market cap$5.25M$5.74M
1-day change-12.75%-6.18%
YTD return—-90.00%
1-year return—-91.80%
5-year return—-99.77%
EPS (TTM)$-11.80$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-15.85M$-26.26M
52-week high$10.54$4.22
52-week low$1.90$0.28
Distance from 52-week high-66.22%-93.20%
Analyst consensusnonestrong_buy
Avg. price target upside+180.90%+2339.02%
Average volume9.30K2.56M
Shares outstanding1.48M20.00M
Employees84
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About CNS Pharmaceuticals

CNSP stock →

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Tempest Therapeutics

TPST stock →

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

CNSP vs TPST FAQ

Which is bigger, CNS Pharmaceuticals or Tempest Therapeutics?

Tempest Therapeutics (TPST) is larger, with a market capitalization of $5.74M compared with $5.25M for CNS Pharmaceuticals (CNSP).

Are CNS Pharmaceuticals and Tempest Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons